Risk factors for the development of gallstone recurrence following medical dissolution

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 6, 2000, Pages 695-700

  Petroni, M Letizia ^a   Jazrawi, Riadh P ^a   Pazzi, Paolo ^b   Zuin, Massimo ^c   Lanzini, Alberto ^d   Fracchia, Mario ^e   Facchinetti, Daniela ^d   Alvisi, Vittorio ^b   Ferraris, Roberto ^e   Bland, J Martin ^a   Heaton, Kenneth W ^f   Podda, Mauro ^c   Northfield, Tim C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b S ANNA HOSPITAL   (Italy)

^c Istituto Biomedico S Paolo   (Italy)

^d SPEDALI CIVILI   (Italy)

^e MAURIZIANO HOSPITAL   (Italy)

^f BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bile acids; Bile salts; Cholelithiasis (diagnosis, epidemiology and prevention); Gallbladder disease; Gallstone recurrence

Indexed keywords

BILE ACID; NONSTEROID ANTIINFLAMMATORY AGENT; STATIN;

ADULT; ARTICLE; ECHOGRAPHY; FEMALE; FOLLOW UP; GALLBLADDER MOTILITY; GALLSTONE; HUMAN; LITHOTRIPSY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SLUDGE;

EID: 0033945066     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012060-00020     Document Type: Article

References (38)

1. 1 Barbara L, Sama C, Morselli Labate AM, Taroni F, Rusticali AG, Festi D, et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology 1987; 7:913-917.
2. 2 Jensen KH, Jorgensen T. Incidence of gallstones in a Danish population. Gastroenterology 1991; 100:790-794.
3. 3 Heaton KW, Braddon FEM, Mountford RA, Hughes AO, Emmett PM. Symptomatic and silent gallstones in the community. Gut 1991; 32:316-320.
4. 4 Attili AF, Capocaccia R, Carulli N, Festi D, Roda E, Barbara L, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology 1997; 26:809-818.
5. 5 Sedaghat A, Grundy SM. Cholesterol crystals and the formation of cholesterol gallstones. W Engl J Med 1980; 302:1274-1277.
6. 6 Ahmed HA, Jazrawi RP, Goggin PM, Dormandy J, Northfield TC. Intrahepatic biliary cholesterol and phospholipid transport in humans: effect of obesity and cholesterol cholelithiasis. J Lipid Res 1995; 36:2562-2573.
7. 7 Holan R, Holzbach RT, Hermann RE, Cooperman AM, Claffey WJ. Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease. Gastroenterology 1979; 77:611-617.
8. 8 Groen AK, Noordam C, Drapers JA, Egbers P, Jansen PL, Tytgat GN. Isolation of a potent cholesterol nucleation-promoting activity from human gallbladder bile: role in the pathogenesis of gallstone disease. Hepatology 1990; 11:525-533.
9. 9 Ahmed HA, Petroni ML, Abu-Hamdiyyah M, Jazrawi RP, Northfield TC. Hydrophobic/hydrophilic balance of proteins: a major determinant of cholesterol crystal formation in model bile. J Lipid Res 1994; 35:211-219.
10. 10 Jazrawi RP, Pazzi P, Petroni ML, Prandini N, Paul C, Adam JA, et al. Postprandial gallbladder motor function: refilling and turnover of bile in health and in cholelithiasis. Gastroenterology 1995; 109:582-591.
11. 11 Festi D, Barbara L, Frabboni R, Morselli Labate AM, Nacchiero MC, Parro S. Prevalence and incidence of gallstone disease: the Sirmione study. In: Recent Advances in the Epidemiology and Prevention of Gallstone Disease. Capocaccia L, Ricci G, Angelico F, Angelico M, Attili AF, Lalloni L, (editors). Dordrecht: Kluwer Academic Publishers; 1991. pp. 7-11.
12. 12 Misciagna G, Leoci C, Guerra V, Chiloiro M, Elba S, Petruzzi J, et al. Epidemiology of cholelithiasis in southern Italy. Part II: risk factors. Eur J Gastroenterol Hepatol 1996; 8:585-593.
13. 13 Lanzini A, Jazrawi RP, Kupfer RM, Maudgal DP, Joseph AEA, Northfield TC. Gallstone recurrence after medical dissolution: an over-estimated threat? J Hepatol 1986; 3:241-246.
14. 14 O'Donnell LDJ, Heaton KW. Recurrence and re-recurrence of gallstones after medical dissolution: a long term follow-up. Gut 1988; 29.655-658.
15. 15 Petroni ML, Jazrawi RP, Lanzini A, Zuin M, Pazzi P, Fracchia M, et al. Repeated bile acid therapy for the long-term management of cholesterol gallstones. J Hepatol 1996; 25:719-724.
16. 16 Villanova N, Bazzoli F, Taroni F, et al. Gallstone recurrence after successful oral bile acid treatment: a 12-year follow up study and evaluation of long term post-dissolution treatment. Gastroenterology 1989; 97:726-731.
17. 17 Hood KA, Gleeson D, Ruppin RH, and the British-Belgian Gall Stone Study Group. Gall stone recurrence and its prevention: the British-Belgian gall stone study group's post-dissolution trial. Gut 1993; 34:1277-1288.
18. 18 Portincasa P, van Erpecum KJ, van de Meeberg PC, Dallinga-Thie GM, de Bruin TWA, van Berge-Henegouwen GP. Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Hepatology 1996; 24:580-587.
19. 19 Petroni ML, Jazrawi RP, Goggin PM, Lanzini A, Facchinetti F, Heaton KW, et al. Characteristics of recurrent gallstones following non-surgical treatment: implications for retreatment. Eur J Gastroenterol Hepatol 1991; 3:473-478.
20. 20 Pelletier G, Raymond JM, Capdeville R, Mosnier H, Caroli-Bosc FX. Gallstone recurrence after successful lithotripsy. J Hepatol 1995; 23:420-423.
21. 21 Berr F, Mayer M, Sackmann MF, Sauerbruch T, Holl J, Paumgartner G. Pathogenic factors in early recurrence of cholesterol gallstones. Gastroenterology 1994; 106:215-224.
22. 22 Sackmann M, Niller H, Klueppelberg U, von Ritter C, Pauletzki J, Holl J, et al. Gallstone recurrence after shock-wave therapy. Gastroenterology 1994; 106:225-230.
23. 23 Adamek HE, Buttmann A, Weber J, Riemann JF. Can aspirin prevent gallstone recurrence after successful extracorporeal shock-wave lithotripsy? Scand J Gastroenterol 1994; 29:355-359.
24. 24 Lee SM, Maher K, Nicholls JF. Origin and fate of biliary sludge. Gastroenterology 1988; 94:170-176.
25. 25 Gross AJ, Clark VA. Survival Distributions: Reliability Applications in the Biomedical Sciences. New York: Wiley; 1975.
26. 26 Johnston DE, Kaplan MM. Pathogenesis and treatment of gallstones. N Engl J Med 1993; 328:412-421.
27. 27 Marks JW, Lan S, and the Steering Committee and the National Cooperative Gallstone Study Group. Low dose chenodiol to prevent gallstone recurrence after dissolution therapy. Ann Intern Med 1984; 100:976-981.
28. 28 Lanzini A, Northfield TC. Assessment of motor function of the gallbladder. J Hepatol 1989; 9:383-391.
29. 29 Festi D, Frabboni R, Bazzoli F, Sangermano A, Ronchi M, Rossi L, et al. Gallbladder motility in cholesterol gallstone disease. Effect of ursodeoxycholic acid administration and gallstone dissolution. Gastroenterology 1990; 99:1779-1785.
30. 30 Spengler U, Sackmann M, Sauerbruch T, Holl J, Paumgartner G. Gallbladder motility before and after extracorporeal shock-wave lithotripsy. Gastroenterology 1989; 96:860-863.
31. 31 Janowitz P, Kratzer W, Zemmler T, Tudyka J, Wechsler J. Gallbladder sludge: spontaneous course and incidence of complications in patients without stones. Hepatology 1994; 20:291-294.
32. 32 Sackmann M, Ippisch E, Sauerbruch T, Holl J, Brendel W, Paumgartner G. Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology 1990; 98:392-396.
33. 33 Levy PF, Smith BF, LaMont JT. Human gallbladder mucin accelerates nucleation of cholesterol in artificial bile. Gastroenterology 1984; 87:270-275.
34. 34 Hood KA, Gleeson D, Ruppin DC, Dowling RH, and the British/Belgian Gallstone Study Group. Prevention of gallstone recurrence by non-steroidal antiinflammatory drugs. Lancet 1988; ii:1223-1225.
35. 35 Duane WC. Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid composition in healthy male subjects. J Lipid Res 1994; 35:501-509.
36. 36 Hoogerbrugge-vd Linden N, de Rooy FW, Jansen H, van Blankenstein M. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut 1990; 31:348-350.
37. 37 Mazzella G, Parini P, Festi D, Bazzoli F, Aldini R, Roda A, et al. Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia. Hepatology 1992; 15:1072-1078.
38. 38 Smit JW, van Erpecum KJ, Renooij W, Stolk MF, Edgar P, Doornewaard H, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995; 21:1523-1529.